CHADD has worked hard to address the shortages, and we are seeing some real changes take place—both in resolving the immediate shortages and in solving the problem long-term. We have been working closely with legislators, peer associations, government agencies, and pharmaceutical companies to get to the causes and to address them.
Over the last six months, CHADD has been busy addressing this serious problem:
- CHADD’s survey in January collected more than 5,500 responses. Forty-nine percent of our respondents were having serious difficulty getting prescriptions filled, and eighteen percent were forced to change to a new medication. Your participation in the survey gave us more information on the shortage than anyone else in the country. Thank you.
- CHADD and the American Academy of Child and Adolescent Psychiatry formed a coalition of concerned associations, which included several pharmacist groups as well as the American Academy of Pediatrics, the American Psychiatric Association, and a number of mental health and ADHD groups.
- CHADD has been in regular communication with all the major pharmaceutical companies to understand the obstacles to manufacturing sufficient quantities of medication.
- CHADD leadership has met with staff for every key committee in both the US House of Representatives and the US Senate to make them aware of the seriousness of the problem.
- CHADD leadership and members of the coalition met with the staff of the Food and Drug Administration to determine their role.
- CHADD worked with the media to get the story out to the larger community. Literally hundreds of media outlets covered the story.
- And the coalition repeatedly asked for a meeting with the Drug Enforcement Agency. We are still waiting.
- In January, the DEA increased the quota for stimulant medications significantly. Because the pharmaceutical companies need time to then manufacture the medications, an increase in the availability of medications did not begin until this spring.
- The House Energy and Commerce Health Subcommittee is investigating the role of the DEA in the shortage and has not yet released a report.
- Senator Chuck Grassley from Iowa has asked the General Accounting Office to investigate the DEA’s role and report on their findings. While such a report can take up to a year, the GAO is known for even-handed, nonpartisan reports and good recommendations.
- The Prescription Drug User Fee Act of 2012 (PDUFA) was approved by the House last week and now faces one last vote in the Senate before going to the President. It instructs the Secretary of Health and Human Services to address medication shortages within thirty days. When the shortage involves a controlled medication, like stimulants, the Secretary has the authority to contact the Attorney General (the Secretary’s counterpart in the Department of Justice, which includes the DEA) and ask that the quota be increased. The Attorney General and the DEA must respond by either taking action or responding with a clear rationale for not increasing the quota. And all of this information must be made public. This is the first time a mechanism has been put in place to address a shortage before it becomes chronic.
Ruth Hughes, PhD
Ruth Hughes, PhD, is the CEO of CHADD.